HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions

Oncogene

Volumn 29, Issue 3, 2010, Pages 411-420

  Villaronga, M A ^a   Lavery, D N ^b   Bevan, C L ^b   Llanos, S ^c   Belandia, B ^a  

^a CSIC   (Spain)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Androgen receptor; HEY1; Notch; P53; Single nucleotide polymorphism

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; LEUCINE; METHIONINE; PROTEIN P53;

ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CODON; CONTROLLED STUDY; DNA MODIFICATION; GENE; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HEY1 GENE; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BINDING SITES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOBLOTTING; LEUCINE; METHIONINE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 75149153252     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.309     Document Type: Article

References (36)

1. Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, Jug G et al. (2008). EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 68: 7100-7109.
2. Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL, Parker MG. (2005). Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol 25: 1425-1436.
3. Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M. (2002). A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet 30: 315-320.
4. Davis RL, Turner DL. (2001). Vertebrate hairy and enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning. Oncogene 20: 8342-8357.
5. Espinosa JM. (2008). Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 27: 4013-4023.
6. Ferre-D'Amare AR, Prendergast GC, Ziff EB, Burley SK. (1993). Recognition by Max of its cognate DNA through a dimeric b/HLH/ Z domain. Nature 363: 38-45.
7. Fuke S, Sasagawa N, Ishiura S. (2005). Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 30 non-coding polymorphic region of the human dopamine transporter (DAT1) gene. J Biochem 137: 205-216.
8. Gartel AL, Radhakrishnan SK. (2005). Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980-3985.
9. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S et al. (2009). Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol 50: 969-979.
10. Huang Q, Raya A, DeJesus P, Chao SH, Quon KC, Caldwell JS et al. (2004). Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci USA 101: 3456-3461.
11. Hulleman E, Quarto M, Vernell R, Masserdotti G, Colli E, Kros JM et al. (2009). A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med 13: 136-146.
12. Hunter KW, Crawford NP. (2006). Germ line polymorphism in metastatic progression. Cancer Res 66: 1251-1254.
13. Iso T, Kedes L, Hamamori Y. (2003). HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194: 237-255.
14. Iso T, Sartorelli V, Chung G, Shichinohe T, Kedes L, Hamamori Y. (2001a). HERP, a new primary target of Notch regulated by ligand binding. Mol Cell Biol 21: 6071-6079.
15. Iso T, Sartorelli V, Poizat C, Iezzi S, Wu HY, Chung G et al. (2001b). HERP, a novel heterodimer partner of HES/E(spl) in Notch signaling. Mol Cell Biol 21: 6080-6089.
16. Itoh F, Itoh S, Goumans MJ, Valdimarsdottir G, Iso T, Dotto GP et al. (2004). Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO J 23: 541-551.
17. Karsenty G. (2008). Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet 9: 183-196.
18. Knudson AG. (2001). Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-162.
19. Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE et al. (2006). Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 172: 909-921.
20. Leong KG, Gao WQ. (2008). The Notch pathway in prostate development and cancer. Differentiation 76: 699-716.
21. Lu C, El-Deiry WS. (2009). Targeting p53 for enhanced radio-and chemo-sensitivity. Apoptosis 14: 597-606.
22. Maier MM, Gessler M. (2000). Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. Biochem Biophys Res Commun 275: 652-660.
23. Nakagawa O, McFadden DG, Nakagawa M, Yanagisawa H, Hu T, Srivastava D et al. (2000). Members of the HRT family of basic helix-loop-helix proteins act as transcriptional repressors downstream of Notch signaling. Proc Natl Acad Sci USA 97: 13655-13660.
24. Pietsch EC, Humbey O, Murphy ME. (2006). Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611.
25. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G et al. (2001). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409: 928-933.
26. Sakamoto M, Hirata H, Ohtsuka T, Bessho Y, Kageyama R. (2003). The basic helix-loop-helix genes Hesr1/Hey1 and Hesr2/Hey2 regulate maintenance of neural precursor cells in the brain. J Biol Chem 278: 44808-44815.
27. Satow T, Bae SK, Inoue T, Inoue C, Miyoshi G, Tomita K et al. (2001). The basic helix-loop-helix gene hesr2 promotes gliogenesis in mouse retina. J Neurosci 21: 1265-1273.
28. Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH. (2007). Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells. Eur J Immunol 37: 2937-2948.
29. Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, Matsunoshita Y et al. (2009). Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 100: 1957-1965.
30. Undevia SD, Gomez-Abuin G, Ratain MJ. (2005). Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5: 447-458.
31. Villaronga MA, Bevan CL, Belandia B. (2008). Notch signaling: a potential therapeutic target in prostate cancer. Curr Cancer Drug Targets 8: 566-580.
32. Whibley C, Pharoah PD, Hollstein M. (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107.
33. Yang J, Weinberg RA. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829.
34. Zamurovic N, Cappellen D, Rohner D, Susa M. (2004). Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem 279: 37704-37715.
35. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. (2004). Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 23: 1155-1165.
36. Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y, Sarkar FH. (2006). Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer 119: 2071-2077.